MAIA Biotechnology, Inc. (MAIA) Form 10-Q — Aug 10, 2026
MAIA Biotechnology's Q2 2026 net loss widened 49% year over year to $7.9 million as research and development spending jumped 81% to $5.6 million, driven by its pivotal Phase 3 THIO-104 trial of lead oncology candidate ateganosine in third-line non-small cell lung cancer. The company ended June with $27.6 million in cash after a March confidentially marketed public offering raised about $33 million gross at $1.50 per share, which management says fully funds the Phase 3 trial; the H.C. Wainwright at-the-market program was terminated in May. Share count grew roughly 57% in six months to 60.8 million shares.
Key figures
- Cash Position
- 27595831
- Shares Outstanding
- 60825844
- Figures note
- netIncome and eps are for the six months ended June 30, 2026
- Working capital
- 21979479
- Cash dec 31 2025
- 8658031
- Total liabilities
- 7565161
- Ga expense q2 2026
- 2677591
- Rd expense q2 2026
- 5639660
- Accumulated deficit
- 123944244
- Thio 101 part c dcr
- 90.5% (19 of 21 patients)
- Antidilutive options
- 16680425
- Warrants outstanding
- 13086220
- Antidilutive warrants
- 13086220
- Net loss yoy change q2
- 49%
- Thio 104 patients dosed
- 29
- Rd expense yoy change q2
- 81%
- Thio 104 sites activated
- 34
- Nci sbir grant commitment
- 2297863
- Total stockholders equity
- 20675010
- Wainwright claim warrants
- 1540411
- Rd expense six months 2026
- 9164757
- Grant income six months 2026
- 420738
- Share count growth six months
- 38,624,289 to 60,817,482 shares (+~57%)
- March 2026 cmpo gross proceeds
- 33008813
- March 2026 cmpo price per share
- 1.5
- Wainwright warrant exercise price
- 1.875
- Warrants weighted avg exercise price
- 1.92
Price after filing
Close on the filing date to close N calendar days later (from $1.42). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.